Anupam Rasayan Acquires Controlling 47.95% Stake in Bliss GVS Pharma
Bliss GVS Pharma Ltd 路 Outcome 路 29 Sept 2026, 2:19 am
Anupam Rasayan Acquires Controlling 47.95% Stake in Bliss GVS Pharma Anupam Rasayan India Limited, alongside PAC Mates Visa Consultancy, acquired control of Bliss GVS Pharma Ltd. on 28th Sep'26, becoming the new promoters. Following the SPA consummation and open offer, the group holds 5,09,86,264 equity shares, representing 47.95% of total share capital. Concurrently, Managing Director Narsimha Shibroor Kamath resigned from his role and board positions. The board approved the appointments of Hetul Krishnakant Mehta, Amar Dilip Shah, and Pramod Badrinarayan Kasat as Non-Executive Non-Independent Directors, subject to shareholder approval via postal ballot.
Original exchange filing (PDF)
More announcements from Bliss GVS Pharma Ltd
- Please find enclosed herewith the Intimation under Regulation 30 of the SEBI Listing Regulations. 路 06 Nov 2026
- We wish to inform you that Asterisk Lifesciences Ltd, UK, a wholly owned subsidiary of Bliss GVS Pharma Limited, has obtained marketing authorization from the Medicines & Healthcare products .... 路 04 Nov 2026
- Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 29 Oct 2026
- Please find enclosed herewith the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss .... 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find enclosed herewith the Outcome of Board Meeting which was held on today i.e. October 29, 2026 路 29 Oct 2026
- Please find attached the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. 路 29 Oct 2026
- Bliss GVS Pharma Limited has informed the Exchange about Board Meeting to be held on 29-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 29 Oct 2026
